Estrella Immunopharma activates Oregon Health & Science University site for STARLIGHT-1 EB103 lymphoma trial
ESLA•Trial remains in expansion phase
No clinical results have been presented; data from the expansion cohort are expected to guide the pivotal trial strategy.
The study aims to further assess EB103’s safety profile and signs of clinical benefit at the recommended Phase II dose.
Oregon Health & Science University added as third U.S. site
Estrella Immunopharma opened Oregon Health & Science University as a third U.S. site for its Phase I/II STARLIGHT-1 trial of EB103 in relapsed or refractory B-cell non-Hodgkin’s lymphoma.
The new site has begun screening patients, supporting broader enrollment as the study moves through its expansion phase.
